Former Sky presenter Dermot Murnaghan diagnosed with stage four prostate cancer
Former Sky News presenter Dermot Murnaghan has announced his diagnosis with stage four prostate cancer.
The broadcaster, 67, who spent more than 15 years at the news channel before his departure in 2023, said he is "responding positively" to treatment in a post to X on Monday.
"Some personal news… I've been diagnosed with Stage IV advanced prostate cancer", he said.
"I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough – they are administering the best possible care with expertise, compassion and sensitivity.
"I'm responding positively to their excellent treatment, and feeling well."
Some personal news……I've been diagnosed with Stage IV advanced prostate cancer I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough - they are administering the best possible care with expertise, compassion and sensitivity.
— Dermot Murnaghan (@DermotMurnaghan) June 23, 2025
Stage four prostate cancer can mean that the cancer has spread into different parts of the body including nearby body organs, such as the back passage or bladder, nearby lymph nodes and other parts of the body outside the pelvis, such as the bones, lungs or liver, according to the Cancer Research UK website.
"I'm blessed to be fortified by the monumental love and support of my wife, family and close friends", Murnaghan said.
"Needless to say my message to all men over 50, in high risk groups, or displaying symptoms, is get yourself tested and campaign for routine prostate screening by the NHS."
Murnaghan presents true crime documentary series Killer Britain and the podcast Legends Of News.
Before joining Sky News, Murnaghan presented ITV's News At Ten and the BBC Ten O'Clock News – now known as BBC News At Ten – as well as Channel 4 News.
Murnaghan also hosted the BBC's quiz programme Eggheads and presented Sky News At Ten and talk show Murnaghan before his last role at the channel as a newsreader on Sky News Tonight.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Irish Sun
10 hours ago
- The Irish Sun
Aspirin could be prescribed to prevent bowel cancer for those in high-risk group
ASPIRIN could be prescribed to try to prevent bowel cancer for those in a high-risk group. A Cancer Research UK study found a small daily dose offers protection for people with Lynch syndrome. More than half of people with the genetic condition develop bowel cancer at some point in their life. Experts will apply for a prescription license to give 'baby' 75mg pills to the nearly 200,000 Brits with Lynch syndrome. CRUK said fewer than half of GPs knew they should prescribe aspirin to Lynch syndrome patients and many were worried about the dose size. The trial found a much smaller dose than the previously recommended 600mg would work, reducing the risk of side effects. READ MORE ON CANCER Professor Sir John Burn, from Newcastle University, said: 'This tells us that aspirin can prevent bowel cancer at lower doses, minimising the chances of side-effects whilst offering vital protection for people with Lynch syndrome. 'Only a quarter of people with Lynch syndrome are currently taking aspirin and too many are missing out on a potentially life-changing opportunity to prevent cancer.' Lynch syndrome is estimated to cause about one in every 33 bowel cancer cases in the UK. Bowel tumours are one of the most common types, with 44,000 cases per year and 17,000 deaths. Most read in Health The 4 signs of bowel cancer that mean it's 'too late' - as doctor reveals cause of surge in young people being diagnosed 1 Aspirin could be prescribed to prevent bowel cancer for those in a high-risk group Credit: Getty What are the red flag warning signs of bowel cancer? IT'S the fourth most common cancer in the UK, the second deadliest - yet bowel cancer can be cured, if you catch it early enough. While screening is one way of ensuring early diagnosis, there are things everyone can do to reduce their risk of the deadly disease. Being aware of the signs and symptoms of bowel cancer, spotting any changes and checking with your GP can prove a life-saver. If you notice any of the signs, don't be embarrassed and don't ignore them. Doctors are used to seeing lots of patients with bowel problems. The five red-flag symptoms of bowel cancer include: Bleeding from the back passage, or blood in your poo A change in your normal toilet habits - going more frequently for example Pain or a lump in your tummy Extreme tiredness Losing weight Tumours in the bowel typically bleed, which can cause a shortage of red blood cells, known as anaemia. It can cause tiredness and sometimes breathlessness. In some cases bowel cancer can block the bowel, this is known as a bowel obstruction. Other signs include: Gripping pains in the abdomen Feeling bloated Constipation and being unable to pass wind Being sick Feeling like you need to strain - like doing a number two - but after you've been to the loo While these are all signs to watch out for, experts warn the most serious is noticing blood in your stools. But, they warn it can prove tricky for doctors to diagnose the disease, because in most cases these symptoms will be a sign of a less serious disease.
Irish Times
19 hours ago
- Irish Times
Trump's drug plan risks higher medicine prices in Europe
European healthcare systems face paying more for drugs or losing access to new treatments as a result of Donald Trump's push for the global medicines industry to cut prices in the US, industry experts have warned. Global drugmakers are in talks with the Trump administration as he pressures them to voluntarily reduce their prices for American patients. Experts say the US president's plan risks significant consequences for European healthcare systems, as both the Trump administration and pharmaceutical companies are likely to seek price increases in Europe to allow for cheaper costs in the US. Trump's so-called most favoured nation drugs policy, set out in an executive order in May, is hanging over the industry's negotiations about changes to its UK pricing agreement, which are due to conclude this month. READ MORE Drugmakers are using the policy as an argument to bolster their case for charging the UK's National Health Service (NHS) more, people familiar with the matter say. The industry fears that if it settles for less with the NHS, the Trump administration could try to cut US drug prices to UK levels. European countries are likely to resist significant price hikes because budgets are stretched and many contracts with companies are long. This could mean drugmakers end up not launching new medicines in markets where the price will be much lower. Trump has accused Europe of being among the world's 'foreign freeloaders' that he says enjoy cheap drugs on the back of the US healthcare system, which pays sky-high prices for branded medicines. The Most Favoured Nation policy pushes drugmakers to offer US patients the lowest price they charge in any country where GDP per capita is at least 60 per cent of US levels. Dustin Benton, managing director at Forefront Advisors, a political risk research firm, said the policy is built on the premise that the administration can pressure European healthcare systems to pay more for drugs. 'The idea being that if Europeans pay more for drugs, then Americans can pay less for drugs', he said, adding that the medicines industry was discovering the 'downside of being multinationals'. 'We think the ultimate goal is if the price in the US is $100 (€86), and in Europe it is $20, Trump wants Europe to come up to $80 or $90, and the US to come down to the same,' said Philip Sclafani, a partner in PwC's life sciences practice. Trump has already shown signs of trying to put pricing pressure directly on other countries through trade deals. The EU would struggle to include promises on medicine prices in its potential trade deal with Washington because member states control their own budget negotiations on drugs. But the UK-US trade deal includes a promise from London that it will 'endeavour to improve the overall environment for pharmaceutical companies operating in the United Kingdom', without specifying what this might mean. The UK is likely to resist dramatic changes to the methodology it uses to value drugs, but it could present any changes to its pricing deal as a victory for Trump, if it could also make that politically palatable at home by winning additional investment from drugmakers. The UK caps the total bill for branded medicines with a clawback tax, and assesses each drug for value for money in a stringent process. Most Favoured Nation threatens pharmaceutical companies' business models, which are based on a large US market where drug prices are on average about 2.3 times higher than in 32 other OECD countries, according to research by the Rand Corporation for the US health and human services department. Companies are likely to try to offer small voluntary changes to the Trump administration. If those fail, legal challenges could follow. A court stopped the policy when Trump tried to introduce it towards the end of his previous administration, but on the grounds that he did not allow enough time for consultation. The industry shares some common ground with the Trump administration, however, as it has for a long time argued that Europe should pay more for drugs. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said Most Favoured Nation was a 'validation of what we have been saying for a long time': that the UK will miss out on investment because it pays so little for drugs. Sclafani said the US administration is asking a lot if it expects the outcome to be an ideal 'pie in the sky world' where America spends less on healthcare and European countries are pushed to spend significantly more, even though this was achieved with Ukraine and defence spending. 'It would be very tough for most European populations to say the price of a drug is going to double,' Sclafani said. The UK health department said it had 'well-established and effective mechanisms for managing the costs of medicines and has clear processes in place to mitigate risks to supply'. The Danish ministry of the interior and health said there was 'free pricing' on pharmaceuticals in Denmark and there would continue to be so, while Germany said the country's assessments of a drug's benefits played a 'crucial role' in pricing. – Copyright The Financial Times Limited 2025
RTÉ News
20 hours ago
- RTÉ News
Former Sky presenter Dermot Murnaghan diagnosed with stage four prostate cancer
Former Sky News presenter Dermot Murnaghan has announced his diagnosis with stage four prostate cancer. The broadcaster, 67, who spent more than 15 years at the news channel before his departure in 2023, said he is "responding positively" to treatment in a post to X on Monday. "Some personal news… I've been diagnosed with Stage IV advanced prostate cancer", he said. "I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough – they are administering the best possible care with expertise, compassion and sensitivity. "I'm responding positively to their excellent treatment, and feeling well." Some personal news……I've been diagnosed with Stage IV advanced prostate cancer I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough - they are administering the best possible care with expertise, compassion and sensitivity. — Dermot Murnaghan (@DermotMurnaghan) June 23, 2025 Stage four prostate cancer can mean that the cancer has spread into different parts of the body including nearby body organs, such as the back passage or bladder, nearby lymph nodes and other parts of the body outside the pelvis, such as the bones, lungs or liver, according to the Cancer Research UK website. "I'm blessed to be fortified by the monumental love and support of my wife, family and close friends", Murnaghan said. "Needless to say my message to all men over 50, in high risk groups, or displaying symptoms, is get yourself tested and campaign for routine prostate screening by the NHS." Murnaghan presents true crime documentary series Killer Britain and the podcast Legends Of News. Before joining Sky News, Murnaghan presented ITV's News At Ten and the BBC Ten O'Clock News – now known as BBC News At Ten – as well as Channel 4 News. Murnaghan also hosted the BBC's quiz programme Eggheads and presented Sky News At Ten and talk show Murnaghan before his last role at the channel as a newsreader on Sky News Tonight.
